Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Pollack

Showing results (121-130 of 265) with videos related to

Pageof 27
Sort By:
Cancer|June 15, 2005
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?Stephen F Andrews, Eric M Horwitz, Steven J Feigenberg, et al.
International Journal of Cancer|October 21, 2010
PKA knockdown enhances cell killing in response to radiation and androgen deprivationHarvey H Hensley, Jean-Michel Hannoun-Levi, Paul Hachem, et al.
Cancer|October 26, 2012
The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomogramsRadka Stoyanova, Niraj H Pahlajani, Brian L Egleston, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostateRobert A Price, Scott Murphy, Shawn W McNeeley, et al.
Translational Andrology and Urology|October 27, 2018
Entering an era of radiogenomics in prostate cancer risk stratificationNachiketh Soodana-Prakash, Radka Stoyanova, Abhishek Bhat, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2005
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancerMark K Buyyounouski, Alexandra L Hanlon, Debra F Eisenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancerHoon K Lee, Warren D D'Souza, Jose-Miguel J Yamal, et al.
BJU International|December 16, 2010
Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610Meena Okera, Kyoungwha Bae, Eric Bernstein, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2007
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancerDeborah A Kuban, Susan L Tucker, Lei Dong, et al.
Oncotarget|February 5, 2017
Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratificationFelix M Chinea, Kirill Lyapichev, Jonathan I Epstein, et al.
Pageof 27

Showing results (121-130 of 265) with videos related to

Sort By:
Pageof 27
Cancer|June 15, 2005
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?Stephen F Andrews, Eric M Horwitz, Steven J Feigenberg, et al.
International Journal of Cancer|October 21, 2010
PKA knockdown enhances cell killing in response to radiation and androgen deprivationHarvey H Hensley, Jean-Michel Hannoun-Levi, Paul Hachem, et al.
Cancer|October 26, 2012
The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomogramsRadka Stoyanova, Niraj H Pahlajani, Brian L Egleston, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostateRobert A Price, Scott Murphy, Shawn W McNeeley, et al.
Translational Andrology and Urology|October 27, 2018
Entering an era of radiogenomics in prostate cancer risk stratificationNachiketh Soodana-Prakash, Radka Stoyanova, Abhishek Bhat, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2005
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancerMark K Buyyounouski, Alexandra L Hanlon, Debra F Eisenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancerHoon K Lee, Warren D D'Souza, Jose-Miguel J Yamal, et al.
BJU International|December 16, 2010
Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610Meena Okera, Kyoungwha Bae, Eric Bernstein, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2007
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancerDeborah A Kuban, Susan L Tucker, Lei Dong, et al.
Oncotarget|February 5, 2017
Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratificationFelix M Chinea, Kirill Lyapichev, Jonathan I Epstein, et al.
Pageof 27